BridgeBio director exercises options and sells shares

BridgeBio Pharma, Inc. director Jennifer E. Cook reported an option exercise-and-sale sequence in common stock.

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. director Jennifer E. Cook reported an option exercise-and-sale sequence in common stock. On July 9, 2026, she exercised stock options covering 148,589 shares at exercise prices of $8.45, $16.75, and $29.00 per share, then sold 148,589 shares of common stock in open-market transactions at prices of $90.00 and $84.00 per share. The sales were effected pursuant to a Rule 10b5-1 sales plan adopted on March 16, 2026.

Filing Explained

The July 9 transactions left the reporting director with 8,383 directly owned common shares, while any issuer-level share-count effect remains unstated.

The July 13, 2026 Form 4 reports BridgeBio Pharma director Jennifer E. Cook’s July 9, 2026 exercise of options for 19,000, 112,422, and 17,167 common shares, followed by sales of 36,167 and 112,422 shares.

After the reported transactions, the filing lists 8,383 common shares directly owned, and the material disclosed consequence is a change in the reporting director’s ownership position; the filing does not state an issuer-level dilution amount.

Under the supplied Form 4 definitions, code M denotes an option or derivative exercise and code S denotes an open-market sale; the filing’s M and S entries therefore describe option exercises followed by sales.

The filing states that the transaction was effected under a Rule 10b5-1 sales plan adopted on March 16, 2026; that disclosure identifies the plan’s adoption date, not the reasons for individual trades.

The three exercised option lines list exercise prices of $8.45, $29, and $16.75, and each derivative position is reported at zero afterward.

The option lines list expiration dates of June 1, 2030, June 22, 2032, and June 21, 2033.

Insider Trade Summary 10b5-1

Exercise and Sale: 148,589 shares ($9.45M approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Cook Jennifer E.

Role Director

Sold 148,589 shs ($13.16M)

Approx. gross sale proceeds $13.16M

Approx. exercise cost $3.71M

Approx. pre-tax spread $9.45M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F2	19,000	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F1, F3	112,422	$0.00	$0.00
Exercise	Stock Option (Right to Buy) F1, F4	17,167	$0.00	$0.00
Exercise	Common Stock F1	19,000	$8.45	$161K
Exercise	Common Stock F1	112,422	$29.00	$3.26M
Exercise	Common Stock F1	17,167	$16.75	$288K
Sale	Common Stock F1	36,167	$84.00	$3.04M
Sale	Common Stock F1	112,422	$90.00	$10.12M

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 8,383 shares (Direct)

Footnotes (4)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
2. F2. 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
3. F3. The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.
4. F4. 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Key Figures

Shares sold: 148,589 shares Sale prices: $90.00 and $84.00 per share Shares exercised: 148,589 shares +3 more

6 metrics

Shares sold 148,589 shares Total common shares sold in open-market transactions on July 9, 2026

Sale prices $90.00 and $84.00 per share Prices for the reported open-market sales of common stock

Shares exercised 148,589 shares Total common shares acquired through option exercises on July 9, 2026

Option exercise price $8.45 per share Exercise price for one stock option tranche converted into common stock

Option exercise price $16.75 per share Exercise price for a second stock option tranche converted into common stock

Option exercise price $29.00 per share Exercise price for a third stock option tranche converted into common stock

Key Terms

Rule 10b5-1 sales plan, Stock Option (Right to Buy), derivative security, open-market sale, +1 more

5 terms

Rule 10b5-1 sales plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted"

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vesting financial

"shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What did BridgeBio Pharma (BBIO) director Jennifer E. Cook report in this Form 4?

Jennifer E. Cook reported exercising stock options for 148,589 shares of BridgeBio Pharma common stock and selling 148,589 shares in open-market transactions at $90.00 and $84.00 per share on July 9, 2026.

How many BridgeBio Pharma (BBIO) shares did Jennifer E. Cook sell and at what prices?

She sold 148,589 shares of BridgeBio Pharma common stock in two open-market transactions at $90.00 and $84.00 per share, according to the Form 4 insider trading report.

What stock options did Jennifer E. Cook exercise in BridgeBio Pharma (BBIO)?

She exercised stock options for a total of 148,589 shares of BridgeBio Pharma common stock at exercise prices of $8.45, $16.75, and $29.00 per share, converting derivative securities into common shares.

Were Jennifer E. Cook’s BridgeBio Pharma (BBIO) share sales under a Rule 10b5-1 plan?

Yes. A footnote states the share sales were effected pursuant to a Rule 10b5-1 sales plan adopted by Jennifer E. Cook on March 16, 2026, indicating the transactions were pre-arranged.

Does the Form 4 show net buying or selling by Jennifer E. Cook in BBIO?

The Form 4 reflects net selling activity. Cook exercised options for 148,589 shares and sold 148,589 shares of BridgeBio Pharma common stock, resulting in a net-sell share balance for the reported transactions.

What types of securities are involved in Jennifer E. Cook’s BBIO Form 4 filing?

The filing involves BridgeBio Pharma common stock and stock options (right to buy), with the options exercised into common shares and then corresponding amounts of common stock sold in open-market transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/13/2026 - 04:41 PM Accepted by SEC EDGAR 07/13/2026 - 04:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Jennifer E.

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		M(1)		19,000	A	$8.45	27,383	D
Common Stock	07/09/2026		M(1)		112,422	A	$29	139,805	D
Common Stock	07/09/2026		M(1)		17,167	A	$16.75	156,972	D
Common Stock	07/09/2026		S(1)		36,167	D	$84	120,805	D
Common Stock	07/09/2026		S(1)		112,422	D	$90	8,383	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.45	07/09/2026		M(1)			19,000	(2)	06/22/2032	Common Stock	19,000	$0	0	D
Stock Option (Right to Buy)	$29	07/09/2026		M(1)			112,422	(3)	06/01/2030	Common Stock	112,422	$0	0	D
Stock Option (Right to Buy)	$16.75	07/09/2026		M(1)			17,167	(4)	06/21/2033	Common Stock	17,167	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.

2. 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.

3. The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

4. 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)